Sugemalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PD-L1, (CD274) |
| Clinical data | |
| Trade names | Cejemly, Eqjubi |
| Other names | CS-1001, WBP-315 |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy.[1] It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 ligands.[1]
The most common side effects include anemia (low red blood cells), increased levels of aminotransferases (liver enzymes), rash, hyperlipidemia (high blood fat levels), hyperglycemia (high blood glucose levels), hyponatremia (low blood levels of sodium), hypokalemia (low blood levels of potassium), proteinuria (protein in urine), abdominal (belly) pain, tiredness, arthralgia (joint pain), hypoesthesia (reduced sensation to touch, pain and temperature), hypothyroidism (underactive thyroid gland) and hypocalcemia (low blood levels of calcium).[1]
Sugemalimab was approved for medical use in China in December 2021,[3][4][5][6][7] the European Union in July 2024,[8] and the United Kingdom in October 2024.[9]
- ^ a b c d Cite error: The named reference
Cejemly EPARwas invoked but never defined (see the help page). - ^ "Cejemly PI". Union Register of medicinal products. 25 July 2024. Retrieved 28 July 2024.
- ^ Dhillon S, Duggan S (April 2022). "Sugemalimab: First Approval". Drugs. 82 (5): 593–599. doi:10.1007/s40265-022-01693-4. PMID 35298827.
- ^ "Cstone Announced New Drug Approval Of Cejemly (Sugemalimab) In China To Potentially Reshape The Landscape Of Immuno-oncology Therapy In Lung Cancer" (Press release). CStone Pharmaceuticals. 21 December 2021. Retrieved 8 November 2024 – via PR Newswire.
- ^ "CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer" (Press release). CStone Pharmaceuticals. 6 June 2022. Retrieved 8 November 2024 – via PR Newswire.
- ^ "CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication" (Press release). CStone Pharmaceuticals. 31 October 2023. Retrieved 8 November 2024 – via PR Newswire.
- ^ "CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma" (Press release). CStone Pharmaceuticals. 8 December 2023. Retrieved 8 November 2024 – via PR Newswire.
- ^ "CStone Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer" (Press release). CStone Pharmaceuticals. 26 July 2024. Retrieved 8 November 2024 – via PR Newswire.
- ^ "CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK" (Press release). CStone Pharmaceuticals. 31 October 2024. Retrieved 8 November 2024 – via PR Newswire.